Tamoxifen's benefit greatest for preventing hormone-dependent breast cancer

January 14, 2003

Tamoxifen reduces the risk of developing breast cancer, but its benefits appear to be limited to women at high risk of the hormone-dependent form of the disease, according to an updated analysis of data from a major trial of tamoxifen. The findings appear in the January 15 issue of the Journal of the National Cancer Institute.

Tamoxifen is a selective estrogen receptor modulator that has been shown in prevention trials to reduce the incidence of estrogen receptor-positive (ER+) breast cancers. However, use of tamoxifen has also been associated with an increase in risk of endometrial cancer and blood clots in the lungs. Because of these risks, the drug is not recommended as a preventive agent for the general population.

Several major trials have attempted to identify a subgroup of high-risk, healthy women that would benefit from tamoxifen. In the Italian Randomized Trial of Tamoxifen, 5,408 women who had undergone a hysterectomy were randomly assigned to receive either tamoxifen or a placebo. An earlier published analysis of the results showed no statistically significant difference in breast cancer incidence between the group receiving tamoxifen and the group receiving a placebo.

In the current update of that data with a median follow-up of 81.2 months, Umberto Veronesi, M.D., and Peter Boyle, Ph.D., of the European Institute of Oncology in Milan, and their colleagues of the Italian Tamoxifen Study Group found that tamoxifen reduced the risk of breast cancer by 82% in women at high risk for ER+ breast cancer. In contrast, tamoxifen use had no significant effect among women at low risk for the disease. Factors that have been suggested to predispose a woman to the ER+ form of the disease include having at least one functioning ovary, having begun menstruation at or before age 13, not having had children before age 24, and being taller than 160 cm (about 5 feet 3 inches).

In addition, among women who had used hormone replacement therapy (HRT) and were in the high-risk group, there was a statistically significant difference in favor of tamoxifen.

The authors note if these findings can be confirmed, it may be possible to limit tamoxifen use for breast cancer prevention to women who are most likely to benefit from the drug.

In an accompanying editorial, Victor G. Vogel, M.D., and Shelly Lo, M.D., of the University of Pittsburgh School of Medicine, say that this updated analysis confirms tamoxifen's role in breast cancer chemoprevention. "What remains unknown is whether this demonstrated reduction in the incidence of breast cancer will ultimately lead to an increased survival or overall health benefit for women at risk, or whether women previously taking HRT should consider tamoxifen for chemoprevention," they write.

They point out that newer agents being evaluated for breast cancer reduction, such as raloxifene and aromatase inhibitors, may be effective without increasing the risk of uterine cancer. "Continued follow-up of the patients in these trials will help to answer these questions in the near future," they conclude.
-end-
Contact: Donata Francese, the European Institute of Oncology, 39-027-200-7047, dfrancese@consulenti-associati.it or Lucia Racca 39-025-748-9224, lucia.racca@ieo.it.

Editorial: Clare Collins, University of Pittsburgh School of Medicine, 412-624-2607; fax: 412-624-3184, collcx@msx.upmc.edu

Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, et al. Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-5.

Editorial: Vogel V, Lo S. Preventing hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:91-3.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.